Rigorous HAZMAT (Hazardous Materials) dry-run involved 75 participants, who deployed 375 ZENEO® Midazolam auto-injectors in challenging conditions, including while wearing protective suits, without ...
CROSSJECT’s ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors Injection ...
Key contribution to the acceleration of the development of ZENEO® Epinephrine Financial support includes mainly grants, as well as subsidized loans France 2030 Plan dedicated to supporting French ...
Chenôve, France - November 6, 2015, 8.30am - CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), specialty pharma company specialized in self-injectable drugs for use in emergency situations, announces that ...
Dijon, France, November 13, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® auto-injector to deliver life-saving ...
CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors Injection ...
Crossject successfully completes a new U.S. summative human factors study to assess the usability of ZENEO® Midazolam, soon to be commercialized globally as ZEPIZURE®, under simulated chemical attack ...
CROSSJECT's ZENEO® needle-free auto-injector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors Injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results